Goel S, Marwah A, Kaushik S, Garg VK, Gupta S. Role of serum interleukin-6 in deciding
therapy for multidrug resistant oral lichen planus. J Clin Exp Dent. 2015;7(4):e477-82.
doi:10.4317/jced.52376
References
1.
Carrozzo M, Uboldi de Capei M, Dametto E, Fasano ME, Arduino P, Broccoletti R, et al. Tumor necrosis factor-alpha and interferon-gamma polymorphisms
contribute to susceptibility to oral lichen planus.
J Invest Dermatol. 2004;122:87-94.
Erratum in: J Invest Dermatol. 2004;123:805. |
|
|
|
2. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman
PB, Thongprasom K. Current controversies in Oral
lichen planus: report of an international concensus meeting. Part 2. Clinical management and
malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:164-78. |
|
|
|
3. Ishii T. Immunohistochemical demonstration of T cell subsets and
accessory cells in Oral lichen planus. J Oral Pathol Med. 1987;16:356-61. PMid:3117990 |
|
|
|
4. Gu
GM, Martin MD, Darveau RP, Truelove E, Epstien J. Oral and Serum IL-6 levels in oral lichen planus patients. Oral Surg Oral
Med Oral Pathol Radiol Endod. 2004;98:673-8. PMid:15583539 |
|
|
|
5. Zhang Y, Lin M, Zhang
S, Wang Z, Jiang L, Shen J, et al. NF-kappaB-dependent cytokines in saliva and serum from
patients with oral lichen planus: a study in an
ethnic Chinese population. Cytokine. 2008;41:144-9. |
|
|
|
6. Sun A, Chia JS, Chang YF, Chiang CP. Serum interleukin-6 level is
a useful marker in evaluating therapeutic effects of levamisole
and Chinese medicinal herbs on patients with oral lichen planus.
J Oral Pathol Med. 2002;31:196-203. |
|
|
|
7. Nibali
L, Fedele S, D'Aiuto F, Donos N. Interleukin-6 in oral diseases: a review. Oral Dis. 2012;18:236-43. |
|
|
|
8. Nishimoto
N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther. 2010;87:483-7. |
|
|
|
9. Dreuw
A, Hermanns HM, Heise R, Joussen S, Rodríguez F,
Marquardt Y, et al. Interleukin-6-type cytokines upregulate
expression of multidrug resistance-associated proteins in NHEK and dermal
fibroblasts. J Invest Dermatol. 2005;124:28-37. |
|
|
|
10. Gasche
C, Reinisch W, Huber WD, Leshinsky-Silver
E, Levine A, Abdul-Baki H, et al. IL-10RA
truncation mutations and Semite populations. Inflamm
Bowel Dis. 2011;17:1438. |
|
|
|
11. Silverman S Jr, Gorsky M, Lozada-Nur F, Giannotti K. A
prospective study of findings and management in 214 patients with oral lichen
planus. Oral Surg Oral
Med Oral Pathol. 1991;72:665-70. PMid:1812447 |
|
|
|
12. Ibrahim SS, Hazzaa HH. Topical pimecrolimus
effect on Fas inducing apoptosis in oral lichen planus, a clinical immunohistochemical
study. J oral pathol Med. 2012;41:315-21. |
|
|
|
13. Swift JC, Rees TD, Plemons JM, Hallmon WW, Wright
JC. William WH. Effectiveness of 1% pimecrolimus
cream in the treatment of oral erosive lichen planus.
J Periodontol. 2005;76:627-35. |
|
|
|
14. Gorouhi
F, Solhpour A, Beitollahi
JM, Afshar S, Davari P, Hashemi P, et al. Randomised
trial of pimecrolimus cream versus triamcinolone acetonide paste
in the treatment of lichen planus. J Am Acad Dermatol. 2007;57:806-13. |
|
|
|
15. Allen BR1, Lakhanpaul M, Morris A, Lateo
S, Davies T, Scott G, et al. Systemic exposure, tolerability, and efficacy of
pimecrolimus cream 1% in atopic dermatitis
patients. Arch Dis Child. 2003;88:969-73. |
|
|
|
16. Volz
T, Caroli U, Lüdtke H, Bräutigam M, Kohler-Späth H, Röcken M, et al. Pimecrolimus
cream 1% in erosive oral lichen planus--a
prospective randomized double-blind vehicle-controlled study. Br J Dermatol. 2008;159:994. |
|
|
|
17. McCaughey C, Machan M, Bennett R, Zone JJ, Hull CM. Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind,
vehicle-controlled study with a 6-week open-label extension to assess
efficacy and safety. J
Eur Acad Dermatol Venereol. 2011;25:1061-7. |
|
|
|
18. Frieling
U, Bonsmann G, Schwarz T, Luger TA, Beissert S. Treatment of severe lichen planus with mycophenolate mofetil. J Am Acad Dermatol. 2003;49:1063-6. PMid:14639385 |
|
|
|
19. Nylander
Lundqvist E, Wahlin YB,
Hofer PA. Methotrexate supplemented with steroid
ointments for the treatment of severe erosive lichen ruber.
Acta
Derm Venereol. 2001;82:63-4. PMid:12013206 |
|
|
|
20. Torti
DC, Jorizzo JL, McCarty MA. Oral lichen planus: a case series with emphasis on therapy. Arch Dermatol. 2007;143:511-5. |
|
|
|
21. Kanwar
AJ, De D. Methotrexate for treatment of lichen planus: old drug, new indication. J Eur Acad Dermatol
Venereol. 2013;27:410-3. |
|
|
|
22. Dalmau
J, Puig L, Roé E, Peramiquel L, Campos M, Alomar A. Successful treatment of
oral erosive lichen planus with mycophenolate
mofetil. J Eur Acad Dermatol Venereol. 2007;21:259-60. |
|
|
|
23. Wee J S, Shirlaw PJ, Challacombe SJ, Setterfield JF. Efficacy of mycophenolate
mofetil in severe mucocutaneous
lichen planus: a retrospective review of 10
patients. Br
J Dermatol. 2012;167:36-43. |
|
|
|
24. Yamamoto T, Yoneda K, Ueta E, Hirota J, Osaki T. Serum cytokine levels in patients with
oral mucous membrane disorders. J Oral Pathol Med.
1991;20:275-9. |
|
|
|
25. Karagouni
EE, Dotsika EN, Sklavounou
A. Alteration in peripheral blood mononuclear cell function and serum
cytokines in oral lichen planus. J Oral Pathol Med. 1994;23:28-35. |
|
|
|
26. Fayyazi
A, Schweyer S, Soruri A,
Duong LQ, Radzun HJ, Peters J, et al. T lymphocytes
and altered keratinocytes express interferon-gamma
and interleukin 6 in lichen planus. Arch Dermatol Res. 1999;291:485-90. |
|
|
|
27. Guo
Y, Xu F, Lu T, Duan Z,
Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer.
Cancer Treat Rev. 2012;38:904-10. |
|
|
|
28. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. Targeting interleukin-6 in
inflammatory autoimmune diseases and cancers. Pharmacol
Ther. 2014;141:125-39. |
|
|
|
29. Nagy SE, Andersson JP, Andersson UG.
Effect of mycophenolate mofetil
(RS-61443) on cytokine production: inhibition of superantigen-induced
cytokines. Immunopharmacology. 1993;26:11–20. PMid:8407281 |